References

  1. Monges G, Coindre J, Scoazec J, Bouvier A, Blay J, Loria-Kanza Y et al. Incidence of gastrointestinal stromal tumors (GISTs) in France: results of the Progist survey conducted among pathologists. Asco Meeting Abstracts. 2007; 25: 10047. Google Scholar

  2. Nilsson B, Bumming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate based study in western Sweden. Cancer. 2005; 103: 821-829. PubMed | Google Scholar

  3. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480. PubMed | Google Scholar

  4. Laurent Doucet. Définition, données récentes en anatomopathologie et biologie moléculaire des tumeurs stromales gastro-intestinales. Bull Cancer. 2006; 93 (numéro spécial): S157-S165. PubMed | Google Scholar

  5. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lacosta J, Longeley BJ et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-46. PubMed | Google Scholar

  6. Medeiros F, Corless CL, Duensing A, Hornickj L, Oliveira AM, Heinrich MC et al. Kit negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004 Jul; 28(7):889-894. PubMed | Google Scholar

  7. Theou-Anton N, Tabone S, Brouty-Boye D, Saffroy R, Ronnstrand L, Lemoine A, Emile JF. Co expression of SCF and KIT in gastrointest- inal stromal tumours(GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer. 2006;94(8):1180-5. PubMed | Google Scholar

  8. HeinrichMC,CorlessCL,DuensingA et al. PDGFRA activating mutations in gastrointest- inalstromal tumors. Science. 2003;299(5607):708-10. PubMed | Google Scholar

  9. Miettinen M, Lasota J et al. Gastrointestinal stromal tumors: Definition, clinical, histological, immunohistochemical and molecular genetic features, and differential diagnosis. Virchows Arch. 200 ; 438: 1-12. PubMed | Google Scholar

  10. Boudet MG, De Mestier P et al. Les tumeurs stromales du tube digestif. J Chir. 2001;138:104-108. PubMed | Google Scholar

  11. Mosnier JF. Les tumours stromales gastro-intestinales: du gène au traitement. Hépato-gastro. 2002;9(6):403-406. PubMed | Google Scholar

  12. Ösgus H, Yilmazlar T. Analysis of prognostic and immunohistochemical factors in GIST with malignant potential. J Gastrenterol Surg. 2005; 9 (3):418-424. PubMed | Google Scholar

  13. Hu X, FORSTER J, Damjanov L. Primary malignant gastrointestinal stromal tumor of the liver. Arch Pathol Lab Med. 2003;127:1606-1608. PubMed | Google Scholar

  14. Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y et al. Gastrointestinal stromal tumor of pancreas: case report with documation of KIT gene mutation. Cancer. 2005; 446-470-2. PubMed | Google Scholar

  15. Yamaura K, Kato K, Miyazawa M, Haba Y, Muramatsu A, Miyata K et al. Stromal tumor of pancreas with expression of c-kit protein: report of case. J Gastrenterol Hepatol. 2004;19:467-470. PubMed | Google Scholar

  16. Scaglia É, Jazeron JF, Diebold MD, Bouché O. Tumeurs stromales gastro-intestinales (GIST). EMC (Elsevier Masson SAS, Paris), Gastro-entérologie. 2010; 9-027-A-15. PubMed | Google Scholar

  17. Coindre JM, Emile JF, Monges G, Ranchère-Vince D, Scoazec JY. Tumeurs stromales gastro-intestinales : définition,caractéristiques histologiques, immunohistochimiques et génétique, stratégie diagnostique. Ann Pathol .2005 ; 25 : 358-358. PubMed | Google Scholar

  18. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002; 33:459-465. PubMed | Google Scholar

  19. Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors. Ann Oncol. 2005;16:566-578. PubMed | Google Scholar

  20. De Matteo RP, Lewis JJ, Leug D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231:51-58. PubMed | Google Scholar

  21. Bonvalot S, Rouquié D, Vanel. Chirurgie des GIST aux stades localisés et métastatiques. Oncologie. 2007;9:102-106. PubMed | Google Scholar

  22. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-8. PubMed | Google Scholar

  23. Landi B, Lecomte T, Berger A, Cellier C. Traitement des tumeurs stromales digestives. Gastroenterol Clin Biol. 2004 ;28 :893-901. PubMed | Google Scholar

  24. Dematteo RP, Heinrich MC, El Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466-77. PubMed | Google Scholar

  25. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23: 70-83. PubMed | Google Scholar

  26. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: clinicopathologic, immunohisto chemical , and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006; 30: 477- 489. PubMed | Google Scholar

  27. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib resistant mutants. Gastroenterology. 2005; 128: 270-279. PubMed | Google Scholar

  28. Debiec-Rychter M, Sciot R, Le CesneA, SchlemmerM, Hohenberger P et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006; 42: 1093-103. PubMed | Google Scholar

  29. Landi B, Bouche O, Blay JY et al. Gastrointestinal stromal tumors (GIST). Gastroentérol Clin Biol. 2006; 30(suppl2): 2S98-2S101. PubMed | Google Scholar

  30. Savage DG, Antman KH. Imatinib mesylate- a new oral targeted therapy. N Engl J Med. 2002;346:683-93. PubMed | Google Scholar

  31. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80. PubMed | Google Scholar

  32. Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-1338. PubMed | Google Scholar

  33. Blay JY. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol. 2009 Aug 12. Google Scholar

  34. Casali PG, Joensuu H, Broto JM et al. Preliminary data of nilotinibin the first-line treatment of patients with metastatic or unresectable gastrointestinal stromaltumors(GIST). J Clin Oncol. 2010;28:15s[abstrTPS332]. PubMed | Google Scholar

  35. Kindler HL, Campbell NP, Wroblewski K et al. Sorafenib in patients with imatinib and sunitinib -resistant gastro intestinalstromaltumors(GIST): final results of a University of Chicago PhaseII Consortium trial. J Clin Oncol. 2011;29 [abstr10009]. PubMed | Google Scholar